Company Northwest Biotherapeutics, Inc. Other OTC
Equities
NWBO
US66737P6007
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Immunotherapies for Cancer
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +14.80% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States, Germany, United Kingdom and Netherlands
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +14.80% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Linda Powers
CEO | Chief Executive Officer | 68 | 07-05-16 |
Alton Boynton
FOU | Founder | 79 | 96-03-17 |
Marnix Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 99-12-31 |
David Innes
IRC | Investor Relations Contact | - | 19-02-25 |
Leslie Goldman
LAW | General Counsel | 78 | 11-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alton Boynton
FOU | Founder | 79 | 96-03-17 |
Linda Powers
CEO | Chief Executive Officer | 68 | 07-05-16 |
Navid Malik
BRD | Director/Board Member | 55 | 12-03-31 |
Joseph Black
BRD | Director/Board Member | 74 | 16-01-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,300,000 | 0 | 0 | 90.84 % |
Stock B | 1 | 1,210,879,427 | 1,099,989,992 ( 90.84 %) | 0 |
Company contact information
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane Suite 800
20814, Bethesda
+240 497 9024
http://www.nwbio.comSector
1st Jan change | Capi. | |
---|---|---|
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |